Menarini began its activities in Naples in 1886 as a small laboratory under the name ‘Farmacia Internazionale’. In 1915 it was transferred to Florence, where its head offices are still located
In 1978 Menarini began joining its resources and energy with other important Italian companies such as Malesci, followed by Guidotti, Lusofarmaco, Lusochimica and F.I.R.M.A.
In 1976 the Diagnostic Division was added to the ethical drug business and in 1994 the OTC Division was started up.
The group has more than 700 skilled scientific consultants in Europe, and a network that covers 90.3% of the population and serves a market of 300 million people.
It has 13 subsidiaries and is aiming at establishing a presence in the East of Europe.
The Menarini Group’s main therapeutic areas include; cardiovascular products, gastrointestinal products, antibiotics/respiratory system products, diabetes drugs and anti-inflammatory agents/analgesics.
Girisan Kariangal reflects on Menarini’s journey from a primarily CSO organization to a robust branded business in India, emphasizing strategic partnerships, acquisitions, and a decisive shift towards dermatology. He outlines…
Head of the Middle East region and GM for the Middle East & Africa affiliate, Basel Thaher outlines his 18-year career at Menarini and discusses the Italian family-run company’s footprint…
Menarini’s general manager for Turkey, the Middle East and Africa Uğur Bingöl discusses the Italian company’s restructuring in the region and its desire to replicate its success in Turkey across…
As the general manager of Menarini Thailand, Thomas Scott Birsinger shares the importance of the Thai affiliate within the company’s operations in the region. He also describes its efforts to…
Uğur Bingöl, general manager of Ibrahim Etem Menarini, speaks of his company’s rapid growth and new product lines. He also describes his take on the Turkish pharmaceutical market and outlines…
Javier Amtmann, the new president of AMIIF, the Mexican association of pharmaceutical innovators, reveals AMIIF’s strategic priorities and key areas of focus. As Chairman of the Board of Menarini Mexico,…
The country manager of Berlin-Chemie / A. Menarini Hungary, Dr. Peter Olah, explains the impact of a more targeted sales force in driving the company in the last three years,…
Menarini’s Turkish subsidiary, Ibrahim Etem Menarini, has adapted to the current pharmaceutical market and is positioned to grow in several segments including their new OTC business, but is constrained by…
Dr. Nikitsch, you started Menarini’s Austrian operations almost 13 years ago. Would you say that Menarini’s presence in Austria today reflects the vision you had for the company in Austria…
You established Menarini’s Irish affiliate in 1999. How have you seen the market evolve over these last 13 years? The major changes in the market have principally occurred in the…
Menarini is an extremely proud Italian company in its origins, but also very reliant on international markets. In 2009 approximately 63% of the group’s consolidated revenues came from abroad. What…
After 67 years in the pharmaceutical industry, of which 45 at the head of Menarini, what would you say have been your personal keys to success? Most of my life,…
This year Menarini will launch several new products in France to add to its current portfolio. Apart from this, can you tell us about activities and position in France? Our…
When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and…
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who…
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added…
As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
See our Cookie Privacy Policy Here
